Gilead Loses Appeal To Fda For Cystic Fibrosis Antibiotic

摘要

Gilead Sciences was unsuccessful in overturning a decision by the FDA's Division of Anti-Infective and Ophthalmology Products requiring the company to conduct an additional clinical study for its antibiotic aztreonam lysine before the agency will approve the drug.